Welcome to our dedicated page for Tiziana Life Sciences Com news (Ticker: TLSA), a resource for investors and traders seeking the latest updates and insights on Tiziana Life Sciences Com stock.
Tiziana Life Sciences Ltd. (NASDAQ: TLSA) is a clinical-stage biopharmaceutical company whose news flow centers on the development of intranasal foralumab, a fully human anti-CD3 monoclonal antibody, and related immunomodulation programs. Company announcements highlight progress in neuroinflammatory and neurodegenerative indications, including non-active secondary progressive multiple sclerosis, early Alzheimer’s disease, and amyotrophic lateral sclerosis (ALS).
News about Tiziana often covers key clinical milestones. Recent releases describe dosing of patients in a Phase 2 randomized, placebo-controlled trial of intranasal foralumab in early Alzheimer’s disease, including evaluation as monotherapy and in combination with FDA-approved anti-amyloid therapies lecanemab and donanemab. Other updates report on the Expanded Access Program in non-active secondary progressive multiple sclerosis and the acceptance of the company’s ALS Phase 2 trial into the ALS MyMatch Program at the Sean M. Healey & AMG Center for ALS.
Investors following TLSA news can also expect regulatory and safety updates, such as the submission of Development Safety Update Reports to the U.S. Food and Drug Administration, which summarize cumulative exposure and safety findings for intranasal foralumab. Corporate and capital markets news includes insider share purchases by senior leadership, decisions regarding proposed public offerings, and participation in industry conferences like BIO-Europe, the Jefferies London Healthcare Conference, and neuroscience-focused forums.
This news page aggregates these company-issued press releases and related coverage, giving readers a centralized view of Tiziana’s clinical progress, regulatory interactions, strategic initiatives such as the planned spinout of IL-6 asset TZLS-501, and visibility events like ringing the Nasdaq Closing Bell. Users interested in TLSA can review this feed to monitor how Tiziana’s immunotherapy and drug delivery programs evolve over time.
Tiziana Life Sciences (TLSA) announced a CEO interview detailing recent patent issuances, including anti-CD3 monoclonal antibodies for Crohn’s Disease and anti-IL-6 monoclonal antibodies for COVID-19. Key points discussed include the clinical pipeline for Foralumab and TZLS-501, intended for treating severe COVID-19 and hepatocellular carcinoma using Milciclib. Tiziana emphasizes its unique position with the fully human monoclonal antibody Foralumab in clinical development. The company is advancing its drug candidates aimed at various diseases.
Tiziana Life Sciences (Nasdaq: TLSA) announced the grant of a patent (No. 10,759,862) by the USPTO for its fully human monoclonal antibody, TZLS-501, aimed at treating COVID-19 and other pulmonary diseases. This antibody targets both IL-6R and IL-6, potentially alleviating cytokine storms in patients. The company plans to expedite clinical development, including GMP manufacturing and toxicology studies, to file an IND for clinical trials by Q1 2021. The patent strengthens Tiziana's IP portfolio as it seeks to utilize inhalation delivery for effective treatment.
Tiziana Life Sciences (Nasdaq: TLSA) announced that the USPTO granted a patent for the combination use of Milciclib with tyrosine kinase inhibitors (TKIs) for treating hepatocellular carcinoma (HCC). This patent (No. 10,758,541) will be published on September 1, 2020. Recent presentations at ASCO2020 highlighted Milciclib's favorable tolerance and promising activity in sorafenib-resistant HCC patients. The company aims to advance clinical evaluations for advanced and recurrent HCC cases. Dr. Shailubhai emphasized the need for combination therapies to overcome drug resistance in HCC.
Tiziana Life Sciences (Nasdaq: TLSA) has been granted a patent by the USPTO for treating Crohn’s disease with Foralumab, a fully human monoclonal antibody. This patent, effective from September 1, 2020, enhances the company's intellectual property portfolio. Tiziana's Phase 1 trial indicated Foralumab’s oral administration was well-tolerated, leading to plans for a Phase 2 trial for moderate-to-severe Crohn’s patients later this year. The innovative oral and nasal delivery methods aim to reduce toxicity and enhance treatment efficacy.
Tiziana Life Sciences (Nasdaq: TLSA) announced management team participation in the BTIG Biotechnology Conference on August 11, 2020, at 2:30 p.m. EDT. The event can be accessed through a live webcast via registration. Tiziana is focused on developing targeted drugs for cancer, inflammatory diseases, and COVID-19, with foralumab entering phase 2 studies for conditions like Crohn’s Disease and multiple sclerosis.
Foralumab is the world's only fully human anti-CD3 mAb in clinical development, with applications in autoimmune diseases.
Tiziana Life Sciences (Nasdaq: TLSA) announced the closure of a registered direct offering, issuing 11,009,615 American Depositary Shares (ADSs) at $5.20 per share, raising approximately $57.25 million. The proceeds will support clinical development of Foralumab, clinical trials for HCC patients with Milciclib, and expedite development of TZLS-501 for COVID-19. The total number of Ordinary Shares post-offering is now 190,559,823. ThinkEquity acted as the placement agent for the offering.
Tiziana Life Sciences plc (NASDAQ: TLSA) has signed agreements with four contract research organizations (CROs) to expedite the clinical development of TZLS-501, a fully human monoclonal antibody targeting IL-6R for COVID-19 treatment. The company plans to initiate human clinical trials in Q1 2021. Key partners include FHI Clinical, STC Biologics, Sciarra Labs, and ITR Laboratories Canada, which will assist with GMP manufacturing, safety studies, and inhalation technology. TZLS-501 aims to address cytokine release syndrome by depleting IL-6 levels directly in patients' lungs.
Tiziana Life Sciences (NASDAQ: TLSA) has reported issuing 2,043,000 ordinary shares in July 2020 under its ATM sales agreement, raising $4,371,289. The total number of ordinary shares now stands at 168,540,593, with each share providing one vote in company meetings. Tiziana is advancing its clinical programs, including phase 2 studies for Foralumab, a pioneering anti-CD3 monoclonal antibody aimed at treating autoimmune conditions like Crohn's Disease and multiple sclerosis, alongside developing treatments for COVID-19.
Tiziana Life Sciences (NASDAQ: TLSA) announced the submission of a patent application for the nasal administration of Foralumab, an anti-CD3 monoclonal antibody, as a treatment for COVID-19. This innovative method could enhance immune response and reduce cytokine storms in patients. The company also reported successful Phase 1 trials for both nasal and oral administrations of Foralumab, which showed positive immunomodulatory effects and no severe toxicities. Tiziana holds exclusive rights for this delivery method, aligning with its focus on advancing immunotherapeutic approaches to treat various diseases.
Tiziana Life Sciences plc announced its intention to apply for a standard listing of its ordinary shares on the Official List and admission to trading on the London Stock Exchange's main market. The directors believe this move will enhance the company's global profile, increase trading liquidity, and attract a broader base of investors. Importantly, the company will not issue new shares or raise capital through this listing. A formal notice regarding the cancellation of trading on the AIM market will follow, with expectations to publish a prospectus by late Q3 or early Q4 2020.